U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.


Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Displaying 1 - 20 of 295 results
Collapse Filters
Expand Filters         +
February 24, 2021

Operation Engage

A comprehensive approach that will target the top drug threat identified by the local DEA division while continuing to focus on drug trafficking, violence, and crime reduction.

January 8, 2021

Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated quantitative and qualitative methods. The document is updated periodically and current as of January 8, 2021, and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

December 30, 2020

Illicit Stimulant Availability in Pennsylvania, 2020

Illicit stimulants, specifically cocaine and methamphetamine, remain a pervasive drug threat in Pennsylvania. PFD offices, state/local law enforcement agencies, and other stakeholders throughout Pennsylvania report persistent increases since 2017 in various indicators that demonstrate availability, such as the total quantity of illicit stimulants seized by law enforcement, identification of seized drugs as illicit stimulants by laboratory analysis, and the presence of illicit stimulants in drug-related overdose deaths.

December 30, 2020

Illicit Opioid Availability in Pennsylvania 2020

The increasing availability of illicit opioids is the most significant drug threat in Pennsylvania. The Philadelphia Field Division (PFD) monitors this threat closely, periodically reviewing multiple data indicators, in conjunction with investigative information, to continually assess the threat, then share analytical findings with stakeholders in federal, state, and municipal governments.

October 27, 2020

DEA and USPS unveil Drug Free USA Forever stamp

On behalf of the nearly 10,000 men and women of the Drug Enforcement Administration that are serving today across the United States and in nearly 70 countries around the world, I want to welcome the United States Postal Service, and all of you watching via livestream, to DEA Headquarters and this important event to dedicate a new first class postage stamp.

October 20, 2020

DEA Acting Administrator Timothy Shea Remarks at Project Safeguard Press Conference

DEA Acting Administrator Timothy Shea delivers remarks at a press conference in the DEA-New England offices in Boston, Mass.


October 6, 2020

DEA Acting Administrator Tim Shea visits Tallahassee, Florida

In 2019 alone, Mexican cartels shipped hundreds of thousands of pounds of methamphetamine in tractor trailers and personal vehicles across our Southwest border and onto our nation’s highways — then headed straight for our cities and towns across America.

September 30, 2020

Remarks by DEA Acting Assistant Administrator Timothy McDermott at the National Healthcare Fraud Takedown Press Conference

Due to the efforts of DEA and our partners, from January 2017 through August 2020, we have seen the number of opioid prescriptions drop nearly 37 percent, a reduction in over 47 percent of opioids dispensed, and most importantly -- an 18 percent drop in prescription overdose deaths over the last two years.

September 22, 2020

DEA Acting Administrator Timothy Shea Delivers Remarks at the Operation DisrupTor Press Conference

DEA Acting Administrator Timothy Shea Delivers Remarks at the Operation DisrupTor Press Conference

Department of Justice, Washington, D.C.

September 22, 2020

September 21, 2020

Counterfeit Controlled Prescription Drug Availability in Pennsylvania and Delaware

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) is advising law enforcement and public health counterparts of the increased availability of counterfeit controlled prescription drugs (CPDs) – commonly sold as legitimate CPDs with most containing fentanyl/ fentanyl-related compounds (FRC) – in Pennsylvania and Delaware.

September 14, 2020

Fentanyl Used in Vape Pens

While the presence of fentanyl powder (lethal in doses as small as two milligrams) poses a public safety threat, the ingestion of fentanyl via vaping poses a threat of unknown consequences to the user and those nearby.

September 10, 2020

Statement by DEA Acting Administrator Timothy Shea - Operation Crystal Shield

Statement by DEA Acting Administrator Timothy Shea - Operation Crystal Shield Press Conference - Phoenix,Arizona September 10, 2020

September 3, 2020

The 2018 Heroin Signature Program

The Drug Enforcement Administration (DEA) Heroin Signature Program (HSP) analyzes hundreds of wholesale-level heroin samples each year to identify the geographic area—Mexico, South America (SA), Southwest Asia (SWA), or Southeast Asia (SEA)—where the samples were manufactured.

September 3, 2020

Prescription Opioid Threat in Pennsylvania, 2020

The PDIP strives to maintain situational awareness of the threat posed by prescription opioids in Pennsylvania, and to share these analyses with stakeholders in federal, state, and municipal governments. In 2013, the PDIP published a Pharmaceutical Threat Assessment for Pennsylvania that found prescription opioid availability and abuse at epidemic levels. In 2016 and 2019, the PDIP published updated assessments detailing prescription opioid availability and abuse trends; this 2020 assessment builds on the previous analyses.

August 11, 2020

The Drug Situation in Delaware 2020

The Drug Enforcement Administration’s (DEA) Philadelphia Field Division (PFD) Intelligence Program conducted an analysis of drug availability and abuse for the State of Delaware. This product highlights significant findings regarding various drug trends since last reported in 2017.

The primary drug threats identified in Delaware are illicit opioids, cocaine, controlled prescription drugs, and methamphetamine. The determination of drug threats in Delaware considers a variety of factors including: availability, threat to public health, community impact, attendant crime, enforcement activity, seizures, drug abuse and treatment statistics, and propensity for abuse.

The PFD Intelligence Program analyzed the following indicators in this assessment: illicit and controlled prescription drug availability; drug prices and purity; and fatal drug-related overdose data.

August 11, 2020

The 2017 Heroin Signature Program Publication

The HSP (Heroin Signature Program) is one essential component of the DEA’s Intelligence Program to identify trends in heroin trafficking and distribution in the United States. The objective of the program is to identify and quantify the chemical components of heroin seized at U.S. ports of entry (POE), all non-POE heroin seizures weighing more than one kilogram, randomly chosen samples, and special requests for analysis. Samples submitted to the HSP undergo in-depth chemical analysis at the DEA Special Testing and Research Laboratory (SFL1). This chemical analysis allows SFL1 to associate the heroin samples with a production process, or “signature,” which is indicative of a particular geographic source area and processing method.

August 10, 2020

Drug-Caused Deaths Investigated by the Washoe County Regional Medical Examiner

Since 2009, Drug Enforcement Administration (DEA) reporting from the Los Angeles Field Division (LAFD) has explored drug-related mortality in the LAFD area of responsibility (AOR), which includes the State of Nevada. In 2019, LAFD personnel reviewed post-mortem toxicology records from the period between 2015 and 2018. These records show that the rate of drug-caused deaths per 100,000 in Washoe County alone increased by more than 130 percent during these four year.

July 8, 2020

Drug Availability in Pennsylvania, 2017-19

DEA's Philadelphia Division conducted a review of laboratory analyzed drug seizures for Pennsylvania. The results of analyzing this data formed the basis for estimating the level of drugs present in Pennsylvania and highlights trends in drug availability. 

June 5, 2020

Vaping and Marijuana Concentrates

DEA's revised and updated drug fact sheet about vaping and marijuana concentrates - what are they, what their origin is, what are the common street names for vaping and marijuana concentrates, what do vapes and various concentrates look like, how they are used/abused, what their effect of their use on the minds and bodies of users including signs of overdose, and their legal status. 

June 5, 2020

Synthetic Opioids - Drug Fact Sheet

DEA's revised and updated drug fact sheet about the class of drugs known as synthetic opioids - what are they, what their origin is, what are common street names for these drugs, what do they look like, how they are abused, what their effect is on the minds and bodies of users including signs of overdose, and their legal status. 

DEA US Badge
United States Drug Enforcement Administration DEA.gov is an official site of the U.S. Department of Justice